TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12508627
Drug: Self Administered
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self Administered Therapy (SAT)
Study: 9660578
Drug: Pentoxifylline 400
Normalized name: pentoxifylline 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline 400 mg three times daily
Study: 17950105
Drug: Atorvastatin (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (average dosage, 20.8 mg/d)
Study: 18566295
Drug: Atorvastatin and
Normalized name: atorvastatin and ezetimibe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin and Fenofibrate
Study: 9205766
Drug: Ebrotidine 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebrotidine 800 mg/d p.o. (Group A)
Study: 9205766
Drug: Indometacin 4
Normalized name: Indometacine
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indometacin 4 mg/kg/d p.o. in 3 divided doses (Group B)
Study: 9205766
Drug: Ebrotidine 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebrotidine 800 mg/d p.o. plus Indometacin 4 mg/kg/d p.o. (Group C)
Study: 8280546
Drug: Background infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Background infusion 10 micrograms kg-1 h-1 (B10)
Study: 8280546
Drug: Background infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Background infusion 4 micrograms kg-1 h-1 (B4)
Study: 8280546
Drug: No background
Approvals — FDA: no, EMA: no, PMDA: no
Description: No background infusion (B0)
Study: 26771733
Drug: Eptifibatide (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eptifibatide (bolus plus infusion) 12-48 hours prior to surgery (N=72 patients)
Study: 26771733
Drug: Eptifibatide (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eptifibatide (bolus plus infusion)
Study: 24345886
Drug: 56.5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 56.5 μg teriparatide
Study: 22652160
Drug: Oxybutynin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybutynin (5 mg) + Trospium Chloride (20 mg) administered 3 times a day and 4 times a day respectively in Group A
Study: 22652160
Drug: Oxybutynin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybutynin (5 mg) + Solifenacin (10 mg) administered 3 times a day and once daily respectively in Group B
Study: 17392649
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate (RBC, 400 mg b.d.), esomeprazole (40 mg/day), amoxycillin (1 g t.d), and tinidazole (500 mg b.d.) with bovine lactoferrin (200 mg b.d)
Study: 17392649
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate (RBC, 400 mg b.d.), esomeprazole (40 mg/day), amoxycillin (1 g t.d), and tinidazole (500 mg b.d.) without bovine lactoferrin
Study: 10197573
Drug: Tomato diet
Normalized name: Tomato
DrugBank: Tomato (DB10573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomato diet (16.5 mg lycopene)
Study: 27614452
Drug: Photoelectric and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photoelectric and musical treatment group (Group 1)
Study: 27614452
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo group (Group 3)
Study: 18629567
Drug: Multifaceted intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multifaceted intervention (mailed reminder, treatment guidelines, educational package)
Study: 16775668
Drug: Xuezhikang (XZK)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuezhikang (XZK) 1,200 mg daily for 6 weeks, then replaced by placebo (XZK discontinued group; n = 25)
Study: 16775668
Drug: Xuezhikang (XZK)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuezhikang (XZK) 1,200 mg daily throughout the study (XZK continued group; n = 25)
Study: 15030293
Drug: Ezetimibe (Zetia)
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe (Zetia) as monotherapy
Study: 15030293
Drug: Ezetimibe coadministered
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe coadministered with statins (simvastatin, atorvastatin, lovastatin, or pravastatin)
Study: 10944137
Drug: High-dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose therapy (HDT) using cyclophosphamide, carmustine, and etoposide (CBV regimen) followed by stem-cell transplantation
Study: 10944137
Drug: Sequential chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential chemotherapy (ifosfamide plus etoposide, asparaginase, and cytarabine)
Study: 8596127
Drug: co-amoxiclav (amoxicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: co-amoxiclav (amoxicillin 875 mg + clavulanic acid 125 mg) twice daily for 10 days
Study: 8596127
Drug: cefixime (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: cefixime (400 mg) once daily for 10 days
Study: 8596127
Drug: ciprofloxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: ciprofloxacin (500 mg) twice daily for 10 days
Study: 2172578
Drug: Enrich (12.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enrich (12.8 g of dietary fiber per 1000 kcal)
Study: 26445227
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Iodine-125 brachytherapy and DP regimen (docetaxel 60 mg/m²/cisplatin 75 mg/m²)
Study: 26445227
Drug: DP chemotherapy
Normalized name: prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DP chemotherapy
Study: 17229894
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg of DHA
Study: 17229894
Drug: 1252 mg
Normalized name: Mg
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1252 mg of DHA + EPA
Study: 14637268
Drug: Urate 1000
Normalized name: methenamine hippurate 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urate 1000 mg intravenously over 1 h
Study: 14637268
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C 1000 mg intravenously over 1 h
Study: 10618558
Drug: Tranilast (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tranilast (300 and 450 mg twice daily for 1 or 3 months)
Study: 2834500
Drug: Kabi 2165
Normalized name: immunoglobulin G, human Injectable Solution [Kabiglobulin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kabi 2165 (n = 40): 2,500 U anti‐Xa preoperatively and evening of operation and 2,500 U anti‐Xa morning and evening daily up to the 9th or 10th day postoperatively
Study: 2834500
Drug: Standard heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard heparin (n = 40): 3,750 U preoperatively and then 8 hourly, adjusted with thrombin time and cephalin + activator time, daily up to the 9th or 10th day
Study: 2834500
Drug: Overall tolerance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall tolerance evaluated from hemoglobin and hematocrit values, intra‐ and post‐operative bleeding, operation wound hematoma, and injection site
Study: 27023086
Drug: TNF-α inhibitors
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TNF-α inhibitors
Study: 25057084
Drug: S-1 maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 maintenance chemotherapy (40 mg/m², twice daily for 14 days; 21 days for a treatment cycle)
Study: 25057084
Drug: S-1 maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 maintenance chemotherapy
Study: 21170108
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy (lamivudine 100 mg/d for 32 weeks + interferon alpha 2b 5 million units every other day for 24 weeks)
Study: 21170108
Drug: Lamivudine monotherapy
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine monotherapy (100 mg/d for 48 weeks)
Study: 21170108
Drug: Interferon monotherapy
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon monotherapy (5 million units every other day for 24 weeks)
Study: 12957262
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy delay of 0-9 days
Study: 12957262
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy delay of 10+ days
Study: 9034556
Drug: Saruplase (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saruplase (80 mg)
Study: 1848607
Drug: Calcium‐entry blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium‐entry blocker flunarizine (random treatment)
Study: 26609642
Drug: Tutomesh TUTOGEN
Normalized name: Autogene cevumeran
DrugBank: Autogene cevumeran (DB17497)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tutomesh TUTOGEN biological prosthesis reinforcement parietal herniorrhaphy (Group B)
Study: 25275513
Drug: α-defensins and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: α-defensins and secretory leukocyte protease inhibitor (SLPI) levels
Study: 22510426
Drug: 10 weekly
Normalized name: donepezil
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 weekly individual child CBT sessions and 2 parent sessions
Study: 19460773
Drug: G‐CSF (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF (5 microg/kg, twice a day for 3 days)
Study: 2729751
Drug: Inspiratory flow
Normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory flow resistive loads (4.5 to 27.0 cm H2O/L/s)
Study: 28426123
Drug: Cabozantinib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib (100 mg daily for 12 weeks)
Study: 19637480
Drug: Agar/alginate combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agar/alginate combination impression
Study: 9037444
Drug: Omeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (40 mg once daily) alone (group A) for 4 weeks
Study: 9037444
Drug: Omeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (40 mg once daily) + tripotassium dicitrato bismuthate (TDB; 240 mg bid) for 4 weeks (group B)
Study: 9037444
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg bid) for 2 weeks + amoxicillin (1 g bid only 2nd week) (group A)
Study: 9037444
Drug: Tripotassium dicitrato
Normalized name: Tripotassium dicitratobismuthate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tripotassium dicitrato bismuthate (TDB) monotherapy for 4 weeks (group B)
Study: 8100221
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral (10 mg) and i.m. (0.5 mg) medication
Study: 8100221
Drug: Multiple oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple oral dosing (5 mg on trial days 1, 2, 3, 5, 7, 9, 11 and 13)
Study: 8100221
Drug: Multiple oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple oral dosing (5 mg on trial days 5 to 14) with initial i.m. loading doses (0.5 mg i.m. on trial days 1, 2 and 4)
Study: 8100221
Drug: i.m. administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.m. administration
Study: 3729461
Drug: IHC (angiotensin-induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: IHC (angiotensin-induced hypertension chemotherapy)
Study: 7797925
Drug: Trivalent cold-adapted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent cold-adapted recombinant (CR) influenza virus vaccine
Study: 7797925
Drug: Monovalent A/H1N1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent A/H1N1, A/H3N2, or B vaccine
Study: 2159706
Drug: Weekly intermittent
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly intermittent regimen of AZT and 2',3'-dideoxycytidine
Study: 2159706
Drug: Weekly alternating
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly alternating regimen of AZT and 2',3'-dideoxycytidine
Study: 2159706
Drug: Monthly alternating
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly alternating regimen of AZT and 2',3'-dideoxycytidine
Study: 30277627
Drug: Intravaginal ulinastatin
Normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal ulinastatin (UTI) administration
Study: 27690682
Drug: Nitroglycerin (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (6 puffs, 2.4 mg sublingual) and glucagon (1 mg intravenously)
Study: 27690682
Drug: Sterile water
Normalized name: sterile water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile water (6 puffs) and hyoscine-n-butyl bromide (20 mg intravenously)
Study: 25427566
Drug: CPP‐ACP‐containing cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPP‐ACP‐containing cream (GC Tooth Mouse, non‐fluoride) after fluoride toothpaste (1,400 ppm NaF)
Study: 23617551
Drug: Budesonide 400
Normalized name: Budesonide 400 microgram/actuation powder for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 400 μg
Study: 23617551
Drug: Budesonide 400
Normalized name: Budesonide 400 microgram/actuation powder for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 400 μg + Formoterol 12 μg
Study: 22084331
Drug: Dosing assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing assessment every 12 weeks (n = 124)
Study: 22084331
Drug: Dosing assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing assessment every 4 weeks (n = 126)
Study: 17218576
Drug: Dexamethasone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.5 mg/kg; maximum, 10 mg)
Study: 16398842
Drug: Bisphosphonate therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisphosphonate therapy (n = 5)
Study: 16398842
Drug: Calcium and
Normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium and vitamin D supplementation combined with bisphosphonate treatment (non-trial patients, n = 11)
Study: 12472324
Drug: rHuEPO (40,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuEPO (40,000 units administered weekly by subcutaneous injection)
Study: 2236459
Drug: Enciprazine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enciprazine (5 mg t.i.d., 10 mg t.i.d., and 20 mg t.i.d.)
Study: 16889458
Drug: Cognitive-behavioral group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral group therapy (CBGT) for 12 weeks
Study: 15605617
Drug: Sertraline 100
Normalized name: sertraline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 100 mg/day for 12 weeks
Study: 15171752
Drug: Troglitazone followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone followed by rosiglitazone (4 mg/day) or pioglitazone (30 mg/day)
Study: 15171752
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no antidiabetic medication)
Study: 11566518
Drug: Topical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthesia (oxybuprocaine 0.4%)
Study: 11566518
Drug: Combined anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined anesthesia (topical anesthesia and propofol sedation)
Study: 9054252
Drug: Dexmedetomidine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine infusion (50 ng.kg-1.min-1 for 30 min before induction, then 7 ng.kg-1.min-1 until end of surgery)
Study: 3608513
Drug: Homologous human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Homologous human fibronectin (300 micrograms/ml), mixed with gentamicin and artificial tears, 4 times a day
Study: 24021497
Drug: Lisdexamfetamine dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine dimesylate (20-50 mg/d)
Study: 21917907
Drug: Leptin administration
Normalized name: leptin
DrugBank: Leptin (DB05098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leptin administration (twice daily injections)
Study: 21917907
Drug: Placebo administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administration (twice daily injections)
Study: 17557312
Drug: Doxapram (respiratory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxapram (respiratory stimulant), dosage and duration not specified
Study: 17007369
Drug: Mizolastine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mizolastine (10 mg once daily for 3 weeks)
Study: 17007369
Drug: Cetirizine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine (10 mg once daily for 3 weeks)
Study: 12781882
Drug: Neoadjuvant chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemoradiation and surgery (concurrent)
Study: 12781882
Drug: Neoadjuvant chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemoradiation and surgery (sequential)
Study: 12413260
Drug: Technique G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Technique G (IVECG signal from guide wire)
Study: 12413260
Drug: Technique G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Technique G
Study: 9669144
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with calcium and vitamin D
Study: 31831363
Drug: DHA-rich fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA-rich fish oil (2400 mg/d) for 8 weeks
Study: 31593702
Drug: Dupilumab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab (300 mg weekly subcutaneous injections)
Study: 20976617
Drug: 16-week Theory
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 16-week Theory of Mind (ToM) treatment
Study: 19135798
Drug: Remifentanil (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (two different clinically relevant doses)
Study: 17303791
Drug: Chromium treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chromium treatment (400 microg of chromium daily in the form of chromium yeast)
Study: 15519185
Drug: methylprednisolone, 5
Normalized name: MethylPREDNISolone, 500 mg injectable powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: methylprednisolone, 5 mg/kg body weight
Study: 15519185
Drug: methylprednisolone, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: methylprednisolone, 10 mg/kg body weight
Study: 7931889
Drug: Intranasal fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal fluticasone propionate, 200 micrograms once daily for 4 weeks
Study: 7931889
Drug: Intranasal fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal fluticasone propionate, 100 micrograms once daily for 4 weeks
Study: 8092559
Drug: Intranasal fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal fluticasone propionate (both dosages)
Study: 3076051
Drug: Sodium fluoride
Normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium fluoride therapy (pure sodium fluoride powder, Ossin, Koreberon)
Study: 3076051
Drug: Sodium fluoride
Normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium fluoride therapy (Koreberon)
Study: 25415292
Drug: 4-drug regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4-drug regimen vs 3-drug arm
Study: 23922746
Drug: L-arginine (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (12 g over 8 hours)
Study: 20671070
Drug: 3 months
Normalized name: TABLET, DOSE PACK, 3 MONTHS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 months post-treatment (T3)
Study: 19439881
Drug: 1% clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% clindamycin lotion (C lotion) twice daily
Study: 19439881
Drug: 1% clindamycin+0.025%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% clindamycin+0.025% tretinoin lotion once nightly (CT lotion)
Study: 19439881
Drug: 1% clindamycin+2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% clindamycin+2% salicylic acid lotion twice daily (CS lotion)
Study: 19439881
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of all treatments
Study: 15656050
Drug: Behavioral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral therapy (weight loss and positional therapy)
Study: 15656050
Drug: CPAP (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP (standard therapy)
Study: 11379377
Drug: Continuous combined
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous combined HRT (conjugated equine estrogen 0.625 mg plus medroxyprogesterone acetate 5 mg)
Study: 11379377
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral estrogen (estriol 2 mg daily)
Study: 11379377
Drug: Unopposed transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unopposed transdermal estrogen (estradiol 50 micrograms/24 h)
Study: 3683485
Drug: Continuous chemotherapy
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous chemotherapy (doxorubicin combined with cyclophosphamide or cyclophosphamide combined with methotrexate, fluorouracil, and prednisone)
Study: 3683485
Drug: Intermittent chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent chemotherapy (stopped after three cycles, repeated only with disease progression)
Study: 29258028
Drug: CBT4CBT (computer-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT4CBT (computer-based Cognitive Behavioral Therapy)
Study: 23852077
Drug: Transdermal diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal diclofenac patches
Study: 23294179
Drug: Combination regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination regimen of glucosamine and low-dose cyclosporin A (C)
Study: 23294179
Drug: Single regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single regimen of low-dose cyclosporin A (S)
Study: 17096678
Drug: Triptorelin (3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptorelin (3.75 mg, single subcutaneous or intramuscular injection)
Study: 17096678
Drug: Degarelix (120-320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Degarelix (120-320 mg, multiple subcutaneous doses)